PURPOSE: The purpose of this study is to evaluate the central benzodiazepine (BZP) receptor binding of iomazenil (IMZ) by pharmacokinetic analysis and to establish a methodology for the diagnosis of CNS disorders with abnormalities in BZP receptor binding. METHODS: BZP receptor binding of IMZ was analyzed kinetically using plasma concentration-time profiles and dynamic single photon emission computed tomography (SPECT) data obtained after the intravenous administration of IMZ to patients with neuropsychiatric disease. The analysis was based on a 3-compartmental model including the processes of both blood-brain barrier (BBB) transport and BZP receptor binding. RESULTS: Hydrolized metabolite of IMZ was detected in plasma, indicating the need for separation by HPLC. The BBB influx clearance and the receptor binding potential of IMZ in the medial temporal region was reduced in the epileptic patient. CONCLUSIONS: Our findings suggest the possibility of detecting the epileptic focus by using our method.
PURPOSE: The purpose of this study is to evaluate the central benzodiazepine (BZP) receptor binding of iomazenil (IMZ) by pharmacokinetic analysis and to establish a methodology for the diagnosis of CNS disorders with abnormalities in BZP receptor binding. METHODS: BZP receptor binding of IMZ was analyzed kinetically using plasma concentration-time profiles and dynamic single photon emission computed tomography (SPECT) data obtained after the intravenous administration of IMZ to patients with neuropsychiatric disease. The analysis was based on a 3-compartmental model including the processes of both blood-brain barrier (BBB) transport and BZP receptor binding. RESULTS: Hydrolized metabolite of IMZ was detected in plasma, indicating the need for separation by HPLC. The BBB influx clearance and the receptor binding potential of IMZ in the medial temporal region was reduced in the epilepticpatient. CONCLUSIONS: Our findings suggest the possibility of detecting the epileptic focus by using our method.
Authors: H F Beer; P A Bläuenstein; P H Hasler; B Delaloye; G Riccabona; I Bangerl; W Hunkeler; E P Bonetti; L Pieri; J G Richards Journal: J Nucl Med Date: 1990-06 Impact factor: 10.057
Authors: A Abi-Dargham; M Laruelle; J Seibyl; Z Rattner; R M Baldwin; S S Zoghbi; Y Zea-Ponce; J D Bremner; T M Hyde; D S Charney Journal: J Nucl Med Date: 1994-02 Impact factor: 10.057
Authors: M Laruelle; A Abi-Dargham; M S al-Tikriti; R M Baldwin; Y Zea-Ponce; S S Zoghbi; D S Charney; P B Hoffer; R B Innis Journal: J Cereb Blood Flow Metab Date: 1994-05 Impact factor: 6.200
Authors: M Laruelle; R M Baldwin; Z Rattner; M S al-Tikriti; Y Zea-Ponce; S S Zoghbi; D S Charney; J C Price; J J Frost; P B Hoffer Journal: J Cereb Blood Flow Metab Date: 1994-05 Impact factor: 6.200
Authors: T R Henry; K A Frey; J C Sackellares; S Gilman; R A Koeppe; J A Brunberg; D A Ross; S Berent; A B Young; D E Kuhl Journal: Neurology Date: 1993-10 Impact factor: 9.910
Authors: Y Onishi; Y Yonekura; T Mukai; S Nishizawa; F Tanaka; H Okazawa; K Ishizu; T Fujita; H Shibasaki; J Konishi Journal: J Nucl Med Date: 1995-07 Impact factor: 10.057
Authors: H M Dey; J P Seibyl; J B Stubbs; S S Zoghbi; R M Baldwin; E O Smith; I G Zubal; Y Zea-Ponce; C Olson; D S Charney Journal: J Nucl Med Date: 1994-03 Impact factor: 10.057
Authors: Grant T Gullberg; Bryan W Reutter; Arkadiusz Sitek; Jonathan S Maltz; Thomas F Budinger Journal: Phys Med Biol Date: 2010-09-22 Impact factor: 3.609